Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1226-3p mimic
- Development stage
- Preclinical
- Lead developer
- Kyungpook National University
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
miR-1226-3p mimic is a synthetic microRNA mimic designed to replicate the activity of endogenous miR-1226-3p. In preclinical oncology research, miR-1226-3p mimic has been investigated for its tumor-suppressive properties. It acts by post-transcriptionally regulating and downregulating several target genes, including aquaporin-5 (AQP5), mucin-1 (MUC1-C), dual specificity phosphatase 4 (DUSP4), HER2, PIK3R2, and AKT1. In breast cancer models, exosome-mediated delivery or transfection of miR-1226-3p mimic inhibits cancer cell migration and metastasis. Additionally, it has been shown to enhance sorafenib sensitivity in hepatocellular carcinoma cells and cisplatin/5-fluorouracil sensitivity in esophageal squamous cell carcinoma cells.
- Other names
- hsa-miR-1226-3p mimichsa-miR1226-3p mimichsa-miR 1226-3p mimicmicroRNA-1226-3p mimicmicroRNA1226-3p mimicmicroRNA 1226-3p mimic
02
Targets
TRAF3PIK3R2 (PI3K regulatory subunit beta)MUC1 (Mucin-1 Antigen)AQP5 (Aquaporin-5)DUSP4ERBB2 (Erb-b2 receptor tyrosine kinase 2)AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)EGFR T790M (Epidermal growth factor receptor T790M mutant)FGF2
Beyond the preview
Go deeper on miR-1226-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-1226-3p mimic.